Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.
Explores the historical aspects of drug development, regulatory agencies, and ethical principles in pharmacology, emphasizing the importance of informed consent and human subject protection.
Explores quantitative proteome profiling for drug target identification through activity-based protein profiling and advanced mass spectrometry techniques.
Explores small molecule drugs for infectious diseases, covering global mortality rates, viral and bacterial injuries, antiviral and antibacterial agents, and the development of COX2 inhibitors.
